This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D61.0 | Synonyms: Fanconi syndrome (anemia), Fanconi anemia, FA, Fanconi pancytopenia, Constitutional aplastic anemia with malformations
In 1927, the Swiss pediatrician Guido Fanconi (1892–1979) first described an unusual aplastic anemia in three siblings accompanied by pancytopenia, skeletal malformations (radial and thumb anomalies), skin hyperpigmentation, growth failure and urinary tract malformations. He made clear that this disease was separate from Fanconi renal tubular acidosis (Fanconi syndrome), although both were named after the same person. Fanconi's first description established the identity of Fanconi anemia as a congenital multisystem disorder distinct from the simple aplastic anemia known at the time.
In the 1960s–1970s, it was confirmed that Fanconi anemia follows autosomal recessive inheritance. In 1977, Schroeder and colleagues discovered the hypersensitivity of Fanconi anemia cells to a chemical crosslinking agent (mitomycin C), and the DEB test subsequently became the diagnostic standard. In 1992, Strathdee and colleagues cloned the first Fanconi anemia gene (FANCC), and to date more than 22 FANC genes have been discovered.
Since the 2000s, as FANCD1 was shown to be the same gene as BRCA2 and monoubiquitination of FANCD2 was identified as a key step in the DNA interstrand crosslink (ICL) repair pathway, Fanconi anemia was redefined as a classic model disease of defective DNA repair. This became a link to other cancer susceptibility syndromes, such as BRCA1/2-related breast cancer.
Fanconi anemia is caused by biallelic defects in the FANC gene family involved in DNA interstrand crosslink (ICL) repair. To date, 22 complementation groups (FA-A to FA-W, etc.) have been identified, each caused by variants in a different gene (FANCA, FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ/BRIP1, FANCL, FANCM, FANCN/PALB2, FANCS/BRCA1, etc.).
FANCA variants are the most common, accounting for about 60–65% of all Fanconi anemia, followed by FANCC (~14%), FANCG (~10%), FANCD2 (~3%) and FANCE (~3%). The frequency of each complementation group varies greatly by ethnicity. In Ashkenazi Jews, a founder effect of the FANCC IVS4+4 A>T variant is observed.
In about 10–15% of patients with Fanconi anemia, mosaicism occurs due to somatic reversion mutations. In this case, the normal FANC gene is restored in blood cells, and the DEB test may be falsely negative. In patients with mosaicism, testing should be performed on cells from non-blood tissues such as fibroblasts.
Most Fanconi anemia follows autosomal recessive inheritance (X-linked inheritance in the case of FANCB). Loss-of-function variants must be present in both alleles for the disease to develop, and carriers (heterozygotes) are phenotypically normal.
FANC proteins form three main functional complexes: ①FANC core complex (FA core complex): composed of FANCA/B/C/E/F/G/L/M, with E3 ubiquitin ligase activity; ②ID complex: the FANCI-FANCD2 dimer, which is ubiquitinated by the core complex and recruited to DNA ICL sites; ③downstream repair proteins: FANCD1 (BRCA2), FANCN (PALB2), FANCS (BRCA1), FANCJ (BRIP1) and others, involved in homologous recombination repair.
There is a partial correlation between specific gene variants and clinical phenotype. Biallelic FANCD1 (BRCA2) variants carry a particularly high risk of early-onset AML and medulloblastoma. The FANCC IVS4+4 A>T variant (Ashkenazi Jewish founder variant) shows a tendency toward severe bone marrow failure along with mild congenital anomalies.
The estimated incidence of Fanconi anemia is about 1–3 per million births, making it a rare disease worldwide. Carrier frequency is estimated at about 1/181 (0.55%) but is markedly higher in certain ethnic groups. The number of patients registered in worldwide patient registry data (Fanconi Anemia Research Fund, etc.) reaches several thousand.
Patients with Fanconi anemia in Korea are registered in the national rare disease registration system, and results of a few domestic cohort studies have been reported. Care is provided at specialized pediatric hematology-oncology centers in Korea, and outcomes of hematopoietic stem cell transplantation are gradually improving. FANCA variants are the most commonly found in Korean patients.
Pancytopenia in Fanconi anemia usually begins at 5–10 years of age, with a mean age of onset of about 7 years. Congenital anomalies are found at birth or early in life, but in some phenotypes with mild or no anomalies, diagnosis may be delayed until aplastic anemia develops.
The FANC protein complexes constitute the core pathway of DNA interstrand crosslink (ICL) repair. Normally, when an ICL is recognized, the FANC core complex monoubiquitinates FANCD2 and FANCI and recruits them to the site of DNA damage. The ICL is then removed through incision of the ICL by nucleases, homologous recombination (mediated by FANCD1/BRCA2, FANCN/PALB2, etc.) and translesion synthesis. When FANC genes are defective, this pathway is blocked, ICLs accumulate and DNA double-strand breaks occur.
Recent studies have shown that endogenous formaldehyde and acetaldehyde physiologically generate DNA ICLs in hematopoietic stem cells. Acetaldehyde, produced in alcohol metabolism (ADH5/ALDH2 pathway), particularly causes DNA damage in Fanconi anemia hematopoietic stem cells. This is consistent with clinical observations in Japanese patients, in whom a much more severe phenotype appears when ALDH2 deficiency and Fanconi anemia overlap.
Accumulation of DNA ICLs hyperactivates the p53 pathway, increasing cell cycle arrest and apoptosis in hematopoietic stem cells. In addition, overproduction of inflammatory cytokines such as TNF-α and IFN-γ causes further suppression of hematopoiesis. As a result, the pool of functional hematopoietic stem cells is progressively exhausted and aplastic anemia develops.
Various congenital anomalies are observed in about 60–75% of patients with Fanconi anemia. The most common physical anomalies are thumb and radial anomalies (hypoplasia, aplasia), seen in about 35–50% of all patients. Skin pigmentation abnormalities (café-au-lait spots, hypopigmented spots, generalized hyperpigmentation) are observed in about 60%. Short stature (~50%), microcephaly (~25%), eye anomalies (microphthalmia, ptosis, strabismus) and renal anomalies (horseshoe kidney, single kidney, renal agenesis, hydronephrosis) are also frequent.
Hematologic symptoms usually begin at 5–10 years of age. The main symptoms are fatigue, pallor and dyspnea due to anemia; bleeding tendency due to thrombocytopenia (purpura, nosebleeds, gum bleeding); and recurrent infections and fever due to neutropenia. In some patients (~25–30%), there are no physical anomalies, and the diagnosis is not made until aplastic anemia develops.
In patients with Fanconi anemia, secondary tumors such as AML/MDS (mean age of onset 14 years), head and neck squamous cell carcinoma (adulthood), gynecologic cancers (cervical cancer, vulvar cancer) and gastrointestinal cancers may develop, and related symptoms may appear.
Congenital anomalies such as short stature, skin pigmentation abnormalities, thumb and radial malformations, microcephaly and genital abnormalities (hypogonadism, cryptorchidism) are important clinical clues. Pallor, cutaneous petechiae and purpura, and hepatosplenomegaly may be observed. Ear dysplasia (small ears, low-set ears) or eyelid abnormalities are sometimes present.
The complete blood count is characterized by pancytopenia, macrocytic red cells (increased MCV) and elevated HbF. Serum EPO is markedly elevated relative to the anemia. Bone marrow biopsy shows hypocellular marrow and fatty replacement. Gonadal dysfunction is evaluated by measuring serum androgens and gonadotropins.
The DEB (diepoxybutane) or MMC (mitomycin C)-induced chromosomal breakage test is the standard diagnostic test for Fanconi anemia. In patients with Fanconi anemia, radial chromosome configurations, chromosome breaks and exchanges increase markedly after DEB treatment (10 times normal or more). When somatic mosaicism is suspected, the test is performed on fibroblasts instead of peripheral lymphocytes.
In children, Fanconi anemia is suspected and a DEB test performed when the following findings are present: ① thumb or radial malformations, ② unexplained pancytopenia or aplastic anemia, ③ café-au-lait spots or hypopigmented spots on the skin, ④ typical growth delay and head and neck malformations. In adults as well, screening for Fanconi anemia is considered in cases such as unexplained MDS/AML or recurrent head and neck squamous cell carcinoma.
Siblings of confirmed patients are screened by DEB testing and genetic testing. HLA typing is performed in parallel to identify potential bone marrow transplant donors at the same time.
When the causative gene variant has been identified in the family, prenatal genetic testing can be performed by CVS (10–13 weeks of gestation) or amniocentesis (15–20 weeks of gestation). With in vitro fertilization, PGT-M can prevent implantation of affected embryos, and the so-called 'savior sibling' concept, in which HLA-matched donors are selected at the same time, is permitted in some countries.
The standard first step in diagnosing Fanconi anemia is the DEB- or MMC-induced chromosomal breakage test. Peripheral blood lymphocytes are cultured and treated with DEB, and then the number of chromosome breaks and radial configurations is quantified. A positive result (exceeding the mean of normal controls by 3–4 standard deviations or more) strongly supports Fanconi anemia.
After a positive DEB test, the causative gene is identified with a multigene FANC panel (NGS-based). Gene confirmation testing is essential for identifying the specific complementation group, predicting prognosis, family genetic counseling and deciding on the transplant approach. Rarely, hard-to-detect variants (intronic splicing, regulatory region variants) must be identified by whole-exome or whole-genome analysis.
Bone marrow aspiration and biopsy evaluate marrow cellularity, morphologic abnormalities and progression to AML/MDS. Bone marrow examination is performed annually or when blood counts change. In adult patients and post-transplant patients, surveillance for secondary tumors, such as head and neck endoscopy, gynecologic examination and colonoscopy, is needed.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for the hematologic phenotypes of Fanconi anemia (aplastic anemia, AML/MDS). In Fanconi anemia, because of the defect in DNA ICL repair, there is hypersensitivity to alkylating agents (cyclophosphamide) and radiation, so standard conditioning doses must be markedly reduced (fludarabine-based reduced conditioning is recommended). Transplantation from an HLA-matched sibling donor is best, with a 5-year survival rate of about 80–90%.
Androgens (danazol, oxymetholone) improve hematopoiesis by stimulating EPO gene transcription, activating telomerase and so on. They show a response rate of about 50–60% before transplantation or in patients for whom transplantation is not possible. Adverse effects such as hepatotoxicity (hepatocellular adenoma, hepatocellular carcinoma, peliosis hepatis), virilization (in female patients) and premature closure of growth plates are monitored regularly.
When treating secondary tumors such as head and neck cancer in patients with Fanconi anemia, radiation and alkylating agent-based chemotherapy should be minimized. Platinum-based chemotherapy is relatively safe. Gene therapy clinical trials inserting a normal FANC gene into autologous hematopoietic stem cells using lentiviral vectors are being conducted in patients with FANCA, and early clinical results have been published.
The long-term survival rate after reduced-conditioning transplantation from an HLA-matched sibling donor is 80–90%. Outcomes of unrelated donor transplantation have gradually improved, with recent reports of 5-year survival rates reaching 70–80%. The median survival of patients treated with androgens alone without transplantation is about age 20–30.
Secondary malignancies are one of the main causes of death in patients with Fanconi anemia. Even after transplantation, the cumulative incidence of solid tumors such as head and neck cancer and vulvar cancer reaches 20–30% by age 40. When AML/MDS develops, transplant outcomes are poor if complete remission is not achieved with pre-transplant treatment.
Endocrine abnormalities (growth failure, hypogonadism, hypothyroidism, diabetes), renal dysfunction, reduced bone density, neurocognitive abnormalities and infertility (due to transplant conditioning and hypogonadism) affect the quality of life of long-term survivors.
Families of patients with Fanconi anemia are given an explanation of carrier risk according to the autosomal recessive mode of inheritance (siblings 1/2, children 1/2), and genetic counseling is provided. All siblings are checked for whether they are affected by DEB testing and genetic testing. HLA-matched individuals among affected siblings are used as bone marrow transplant donors.
Carcinogenic risk factors such as tobacco, alcohol (aldehyde production) and HPV infection should be avoided, and HPV vaccination (Gardasil 9-valent) is strongly recommended. From adulthood, regular head and neck endoscopy (every 6–12 months), gynecologic examination (annually) and colonoscopy are performed.
Even after transplantation, surveillance for secondary tumors, monitoring of endocrine function, bone density testing and HPV vaccination (after immune reconstitution) continue. Regular follow-up is essential for early detection and treatment of transplant-related complications (chronic graft-versus-host disease, infection).